Othman Mueen Mohammed

Mr. Othman Mueen Mohammed

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in South Asian Research Journal of Biology and Applied Biosciences
Verified
Journal Article
Closed access
SKSaif al Deen M. Khatlan
Saif al Deen M. Khatlan
RHRokan H. Hamad
Rokan H. Hamad
Othman Mueen MohammedOthman Mueen Mohammed
Othman Mueen Mohammed
AKAli Y. Khudhair
Ali Y. Khudhair
Nonsteroidal anti-inflammatory medications (NSAIDs) are frequently recommended to treat rheumatologically and inflammatory diseases as well as to relieve pain. Acute kidney injury (AKI), chronic kidney disease (CKD), acute interstitial nephritis, and renal papillary necrosis are among the serious renal hazards that NSAIDs are linked to, despite their effectiveness, particularly in people who already have kidney disease or those using NSAIDs long-term or at high doses. This umbrella review consolidates evidence from multiple meta-analyses and systematic reviews to clarify the nephrotoxic potential of NSAIDs. The review reveals that NSAID use, including both traditional and selective COX-2 inhibitors, is linked to a 50% to 70% increased risk of AKI and CKD. Adverse effects are primarily related to intrarenal vasculature disruption, glomerular damage, and sodium imbalance. Although some NSAIDs offer specific renal protections, overall, the harm often outweighs the benefits. Further research is needed to better understand these risks, especially the molecular mechanisms underlying NSAID-induced kidney damage and to identify at-risk populations. This understanding will aid in balancing the therapeutic benefits of NSAIDs against their potential renal risks, ensuring safer clinical use.

7 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
DCDIANA VICTORIA NAVARRETE CARRIOLA
DIANA VICTORIA NAVARRETE CARRIOLA
LVLenci K. Vázquez-Jiménez
Lenci K. Vázquez-Jiménez
APALMA PAZ
ALMA PAZ
BWBaojie Wan
Baojie Wan
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Background/Objectives: Nifuroxazide (Nfz) is a drug that has been used as a scaffold for designing antimicrobial and antiparasitic agents. This study aimed to synthesize and evaluate in vitro of Nfz and twenty-five 4-hydroxybenzhydrazone derivatives as potential anti-Trypanosoma cruzi, anti-Leishmania mexicana, and anti-Mycobacterium tuberculosis agents. Methods: The compounds were synthesized by condensing 4-hydroxybenzhydrazide with appropriate aldehydes in acidic conditions and structurally confirmed by spectroscopic techniques. All compounds were evaluated in vitro against T. cruzi strains (NINOA and A1), L. mexicana (M379 and FCQEPS strains), and M. tuberculosis (H37Rv strain), followed by enzymatic assays against T. cruzi cysteine proteases. Results: Compound Nfz-24 (IC50 = 6.8 μM) had better trypanocidal activity than the reference drugs benznidazole (IC50 > 30 μM) and nifurtimox (IC50 > 7 μM) against the NINOA strain, and Nfz-8 (IC50 = 7.2 μM) was the compound most active against the A1 strain with a high inhibition of T. cruzi cysteine proteases (IC50 = 4.6 μM) and low cytotoxic effects (CC50 >100 μM). On the other hand, compound Nfz-5 (IC50 = 5.2 μM) had a 25-fold better leishmanicidal effect than glucantime (IC50 > 125 μM) against the L. mexicana M379 strain, and compound Nfz-13 had the best leishmanicidal effects (IC50 = 10.2 μM) against the FCQEPS strain. Finally, Nfz, Nfz-1, and Nfz-2 had minimum inhibitory concentration (MIC) values of 12.3, 5.1, and 18.8 μg/mL against M. tuberculosis, respectively. Conclusions: In summary, these results suggest that the compounds Nfz-1, Nfz-2, Nfz-5, Nfz-8, Nfz-10, Nfz-15, Nfz-24, and Nfz-25 are candidates for further studies to develop new and more potent anti-T. cruzi, anti-leishmaniasis, and anti-M. tuberculosis agents.

6 September 2024 in South Asian Research Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Othman Mueen MohammedOthman Mueen Mohammed
Othman Mueen Mohammed
SKSaif Al Deen M. Khatlan
Saif Al Deen M. Khatlan
SNSaif Subhi Noori
Saif Subhi Noori
ISIbrahim Salam
Ibrahim Salam
Mebendazole was introduced in 1971 and is not soluble in water or other organic solvents, it is also not absorbed from the intestinal tract in a high-fat context. Both albendazole and mebendazole have a low rate of absorption in the human intestine. These drugs primarily target parasites in the stomach's lumen, and their metabolites are effective against parasites in the stomach's muscles and tissues. For instance, albendazole sulfoxide is the primary metabolite that possesses anthelmintic properties. Metabolites of mebendazole are expelled in the urine. Both drugs negatively affect the function of microtubules in parasites and mammalian cells, this results in the depletion of the parasites' glycogen stores. Current helminth control strategies involve periodic deworming with albendazole or mebendazole. However, concerns about drug resistance and the persistence of high prevalence rates suggest the need for additional strategies, such as improved water, sanitation, and hygiene, and optimized treatment regimens. Albendazole and mebendazole are highly effective against Ascaris lumbricoides, with a single dose of albendazole showing a cure rate of 96% and mebendazole showing a cure rate of 92.3%. Mebendazole's efficacy against hookworms varies, but a recommended dosing regimen improves effectiveness. Mebendazole's effectiveness against Trichuris trichiura depends on the dosing regimen. It is less effective against hymenolepiasis, where praziquantel is preferred. Mebendazole has also been used to treat Giardia lamblia infections. In summary, STH infections are a significant health issue, and albendazole and mebendazole are commonly used drugs for treatment. However, there is a need for additional strategies to address drug resistance and improve treatment efficacy. Mebendazole has potential side effects and should be used with caution, especially during pregnancy.


9 October 2024 in South Asian Research Journal of Biology and Applied Biosciences
Verified
Journal Article
Closed access
Othman Mueen MohammedOthman Mueen Mohammed
Othman Mueen Mohammed
KMKhloud K. Mohsen
Khloud K. Mohsen
GRGildardo Rivera
Gildardo Rivera
NKNajlaa Abboud Kamel
Najlaa Abboud Kamel
SNSaif Subhi Noori
Saif Subhi Noori
AHAnas Abdullah Hamad
Anas Abdullah Hamad
Leishmaniasis treatment has faced challenges with pentavalent antimonials, historically used but now showing resistance and high failure rates. The World Health Organization (WHO) recommended higher doses, but resistance in Nepal and misuse persist. Antimonials are no longer the preferred treatment for visceral leishmaniasis (VL) in the Indian subcontinent but are still used for cutaneous leishmaniasis (CL). Amphotericin B, especially liposomal amphotericin B (L-AmB), has become the preferred treatment for VL in the Indian subcontinent, with high efficacy and shorter treatment courses. Genetic insights into leishmaniasis reveal that parasite species and host immune responses are key factors in disease variation. Genetic analysis of atypical parasite isolates shows that genetic variations can lead to different disease patterns. Whole genome sequencing and proteomic analyses offer fresh insights into how parasite genes and proteins impact drug resistance, post-kala-azar dermal leishmaniasis (PKDL), and unusual disease presentations. Variations in hereditary unit copy numbers and single nucleotide polymorphisms contribute to genetic diversity and distinct tissue distribution, leading to distinct disease patterns. Genomic markers for drug resistance in Leishmania parasites include ATP-binding cassette (ABC) transporters, amino acid permease 3 (AAP3), and proteins like phosphoglycerate kinase (PGK) and mitogen-activated protein kinase (MAPK). These markers are associated with efflux of thiols and metals, antimony resistance, and protection against oxidative stress. Additionally, key proteins and enzymes in antioxidant defense mechanisms, such as iron superoxide dismutase-A (FeSOD-A), folate transporter 1 (FT1), and heat shock protein 83 (HSP83), play roles in drug resistance and parasite survival.

1 June 2026 in International Journal of Biology Sciences
Verified
Journal Article
Closed access
MMMohammed A Mohammed
Mohammed A Mohammed
MAMouhaned Y Al-Darwesh
Mouhaned Y Al-Darwesh
YMYahya A Mohammed
Yahya A Mohammed
Othman Mueen MohammedOthman Mueen Mohammed
Othman Mueen Mohammed
NKNajla Abbood Kamel
Najla Abbood Kamel